Skip to main content
INFU logo

INFU · InfuSystem Holdings, Inc

Track INFU — free
$14.26 +0.20 (+1.42%)
Market Cap
$281.67M
Shares
20.03M
Volume · Nov 20 99.77K Avg daily vol (3M) 134.57K

Price & Indicators

 

Key stats

Close
$14.06
Thu 19 Nov
Open
$14.69
Thu 19 Nov
Average volume, 30 days
147K
shares a session
Short interest
683K
3.4% of shares · 5.7 days to cover
Day range
$14.00$14.89
Open $14.69 Close $14.06
52-week closing range
$7.42$15.28
Close $14.06 8.0% under the high
Short volume, last session
41%
Last earnings
Nov 3, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 9
Current report 8-K
Net revenue $143.4M; adjusted EBITDA $31.5M

InfuSystem Holdings, Inc. reported 2025 net revenue of $143.4M, up 6% year over year, and adjusted EBITDA of $31.5M, up 25%, with adjusted EBITDA margin of 21.9%.

Regulation FD disclosure
2 source passages
InfuSystem Holdings, Inc. (the “Company”) hereby furnishes the information set forth in the Investor Presentation dated November 9, 2026, which is attached hereto as Exhibit 99.1. 2025 strong financial performance and profitability expansion Consistent Growth Margin Expansion Cash Generation & Reserves Net Revenue +6% YoY Adj. EBITDA +25% YoY Adj. EBITDA Margin +3.1% YoY Operating Margin +3.2% YoY Operating Cash Flow +19% YoY Liquidity Most Recent Completed Fiscal Year $143.4M $31.5M 21.9% 8.3% $24.4M $58.2M Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Patient Services growth offsets Device Solutions revenue decline

For the three months ended September 30, 2026, InfuSystem Holdings, Inc. reported net revenues of $37.6 million, up 3.0%, with Patient Services revenue rising 15.4% and Device Solutions revenue falling 16.6%; gross margin increased to 57.8%.

Revenue $37.59M ▲ 3.0% Net income $3.16M ▲ 39.7% Diluted EPS $0.15 ▲ 36.4%
Read from the MD&A section
5 source passages
InfuSystem Holdings, Inc. Results of Operations for the Three Months Ended September 30, 2026 Compared to the Three Months Ended September 30, 2025 Net revenues for the quarter ended September 30, 2026 (“third quarter of 2026”) were $37.6 million, an increase of $1.1 million, or 3.0%, compared to $36.5 million for the quarter ended September 30, 2025 (“third quarter of 2025”). Patient Services net revenue of $25.8 million increased $3.4 million, or 15.4%, during the third quarter of 2026 compared to the prior year period. Device Solutions net revenue of $11.8 million decreased $2.3 million, or 16.6%, during the third quarter of 2026 compared to the prior year period. Gross margin was 57.8% during the third quarter of 2026 compared to 57.1% during the prior year period, an increase of 0.7%. Open the document at this passage
Nov 5
Current report 8-K
Third-quarter revenue rises 3.0%, Adjusted EBITDA reaches $9.4 million

InfuSystem Holdings, Inc. reported third-quarter net revenues of $37.6 million, up 3.0%, net income of $3.2 million and Adjusted EBITDA of $9.4 million at a 24.9% margin; it reaffirmed 2026 pro-forma revenue growth guidance of 6% to 8%.

Financial results
6 source passages
Rochester Hills, Michigan, November 5, 2026 – InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2026. Net revenues totaled $37.6 million, an increase of 3.0% vs. prior year. Net income was $3.2 million, or $0.15 per diluted share vs. prior year net income of $2.3 million, or $0.11 per diluted share. Adjusted EBITDA (non-GAAP) was $9.4 million, an increase of 12% vs. prior year. Adjusted EBITDA margin was 24.9%, an increase of 2.1% vs. prior year. InfuSystem is reaffirming annual net revenue guidance for the full year 2026. After adjusting for the impact of the reduced revenue related to the GE Healthcare contract restructuring, pro-forma net revenue growth is estimated to be between 6% and 8% for 2026. Open the document at this passage
Nov 3
Earnings call
Wound care drives growth as 2026 guidance is reaffirmed

InfuSystem Holdings reported revenue of $37.6 million, up 3%, and pro forma growth of 10.2% as wound care rose 112%. Adjusted EBITDA was $9.4 million with a 24.9% margin, and reaffirmed 2026 pro forma growth guidance of 6% to 8%.

5 source passages
InfuSystem Holdings 3rd Quarter 2026 Financial Results Conference Call. Third quarter revenue increased 3% to $37.6 million. After adjusting for the impact of the GE Healthcare contract restructuring, revenue grew 10.2% on a pro forma basis. Wound care revenue increased 112% during the quarter, including approximately $1.6 million of growth from compression therapy products. Adjusted EBITDA increased 12.5% to $9.4 million, and adjusted EBITDA margin expanded to 24.9%, compared to 22.8% in the prior year period. We continue to expect pro-former revenue growth of 6% to 8% for 2026 after adjusting for the impact of the GE Healthcare contract restructuring, and continue to expect adjusted EBITDA margins to remain in the low to mid 20% range. Open the document at this passage
Nov 3
Current report 8-K
Results postponed amid ERP accounting review

InfuSystem Holdings, Inc. postponed third-quarter financial results for the period ended September 30, 2026 while evaluating whether new ERP system implementation costs should be capitalized rather than expensed.

Regulation FD disclosure
2 source passages
Rochester Hills, Michigan, November 3, 2026 — InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that it has postponed the release of its financial results for the third quarter ended September 30, 2026, which had previously been scheduled for today. The Company, together with its Audit Committee and its independent registered public accounting firm, is evaluating whether certain implementation costs for its new ERP system, which went live on March 1, 2026, should be capitalized and amortized over the remaining three-year term of the software subscription agreement rather than expensed as incurred. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$144.44M
Trailing 12 months
Net income (TTM)
$9.44M
Trailing 12 months
Revenue growth YoY
+3.0%
Year over year
Operating margin
9.8%
Trailing 12 months
P / E (TTM)
32.0
Trailing earnings · reciprocal yield 3.1%
FCF yield
8.8%
TTM · current market cap
Return on invested capital
13.5%
Trailing 12 months
Net cash
−$10.58M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.6%
Year over year · more shares
Price change (1Y)
+51.5%
Trailing year
Short interest
3.4%
Latest settlement · 5.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. InfuSystem reported Q2 2026 net revenues of $36.9 million (up 2.6%, or 7.5% pro forma), record Adjusted EBITDA of $8.6 million with margin expansion to 23.4%, driven by strong Patient Services growth, while Device Solutions revenue fell 16.1% on the GE Healthcare restructuring. The company reaffirmed full-year 2026 pro forma revenue growth guidance of 6%–8% and mid-to-low 20%s Adjusted EBITDA margin.

Bullish
  • + Patient Services revenue surged 15.2% YoY, led by Wound Care up 154% on new lymphedema compression offerings.
  • + Company reaffirmed full-year 2026 pro forma revenue growth guidance of 6%–8% and mid-to-low 20%s Adjusted EBITDA margin.
Bearish
  • − Device Solutions revenue fell 16.1% YoY to $12.1 million, with biomedical services down 39.4% on the GE Healthcare contract restructuring.
  • − Patient Services gross margin contracted 2.4 points to 61.8% on unfavorable mix toward lower-margin Wound Care and higher pump maintenance costs.
  • − G&A expenses rose 7.2% to $14.1 million and rose to 38.2% of revenue from 36.5%, driven by higher stock comp, wages, and healthcare inflation.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +31%
above
Price vs 50-day avg +4%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 84%
mid-range
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +57%
trailing
YTD return +57%
this year
Relative strength +63%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+23% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.41% of shares out · ▼ -16.0% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
123 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Strong
Revenue growth +6%
Y/Y
Gross margin 56%
expanding
EPS growth +182%
Y/Y
Free cash flow $23.8M
Valuation P/E 32
in line
Buyback $20.0M
authorized
Balance sheet $16.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −24%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 4
Latest guidance · from the 8-K filed Nov 5, 2026
Pro-forma net revenue growth · for 2026 Non-GAAP Maintained 6% – 8%
Aug 4, 2026 6% – 8% changed to Nov 5, 2026 6% – 8%
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Annual revenue growth · annual 6% – 8%
Adjusted EBITDA margin (longer-term target) · longer-term 22% – 25%
Pro forma annual revenue growth · annual 6% – 8%
Guided vs delivered · last 4 settled
Net revenue growth / net revenues full year 2023
guided $118M – $121M
$125.79M Beat +5.3%
Total revenue full year 2022
guided $112M
$109.91M Miss −1.9%
Revenue 2021
guided $107M – $110M
$102.38M Miss −5.6%
Net revenue 2020
guided $94M – $97M
$97.39M Beat +2.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+31% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+23% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.41% of shares out · ▼ -16.0% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
123 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $14 · 84% Range high $15
vs 200-day avg +31% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross margin 57.8% the three months ended September 30, 2026 filing —
Net operating lease revenue 8.15M the three months ended September 30, 2026 filing —
Patient Services gross margin 61.5% the three months ended September 30, 2026 filing —
Sales-type lease revenue 127K the three months ended September 30, 2026 filing —
Available borrowing capacity under revolving line of credit $55M as of September 30, 2026 —
Available liquidity $64.1M as of September 30, 2026 —
Common stock repurchased under share repurchase program $5M nine-month period of 2026 —
Net debt (non-GAAP) non-GAAP $10.6M as of September 30, 2026 —
Non-GAAP Pro-Forma Net Revenue Growth from Prior Year non-GAAP 10.2% third quarter of 2026 —
Operating cash flow $18.1M nine-month period ended September 30, 2026 —
Pro-forma revenue growth 10.2% 2026 Third Quarter —
Purchases of medical devices $8.7M nine-month period of 2026 —
Ratio of net debt to Adjusted EBITDA (non-GAAP) non-GAAP 0.32 last four quarters as of September 30, 2026 —
Trailing four quarter Adjusted EBITDA non-GAAP $33.1M last four quarters as of September 30, 2026 —
Ratio of Adjusted EBITDA to net debt (non-GAAP) non-GAAP 0.61 the last four quarters —
Stock repurchases $3.5M the quarter —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
INFU
InfuSystem Holdings, Inc
this stock
$281.67M +56.7% +6.4% 32.0 3.4%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
123
% held
79.8%
Net QoQ
+864.1K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
130
View
Short & Settlement
Short Interest Falling
Shares short
683.1K
Days to cover
5.7d
Change
-130.3K sh
View
Short Volume
Short vol %
41%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1.9K
Value
$24.4K
As of
Sep 28, 2026
View
Off-Exchange
Off-exchange %
41.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$143.4M
Net income (FY)
$6.6M
EPS diluted
$0.31
View
Buybacks
Authorized
$20.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
24

For the three months ended September 30, 2026, InfuSystem Holdings, Inc. reported net revenues of $37.6 million, up 3.0%, with Patient Services revenue rising 15.4% and Device Solutions revenue falling 16.6%; gross margin increased to 57.8%.

View
Proposed Sales
Value
$56.5K
Shares
5.8K
Filed
Aug 22, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 3, 2026
View
Investor Relations
Latest news
InfuSystem Announces Financial Re…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
INFU -4.9% -0.6% +57.1% -0.1% +56.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.5% +5.7% +62.7% +5.2% +51.8%

Capital returns

Buyback program · as of May 12, 2026
Authorized
$20.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1337013 CUSIP 45685K102 13F (30d) 131 filings 116 filers Visit website Investor relations